Business
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
CULVER CITY, Calif., February 27, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company’s clinical trial pipeline, and to review financial results for the year ended December 31, 2025.
About this update from Immunitybio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/ded252cb1860e1ef3eecc531f58f8dd5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xJtTqHlQ2Vw.kIMZHH7L7g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ded252cb1860e1ef3eecc531f58f8dd5","width":480,"height":270}},"lazy":false},{"type":"text","content":"CULVER CITY, Calif., February 27, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company’s clinical trial pipeline, and to review financial results for the year ended December 31, 2025.","length":365,"tagName":"p"},{"type":"text","content":"Conference Call Details","length":23,"tagName":"p"},{"type":"text","content":"The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally). To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.","length":477,"tagName":"p"},{"type":"text","content":"A replay of the conference call will be posted on our Investor Relations website after the event and will be available for replay for at least 90 days after the event.","length":167,"tagName":"p"},{"type":"text","content":"About ImmunityBio","length":17,"tagName":"p"},{"type":"text","content":"ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Our approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. At the core of our strategy is the Cancer BioShield™ platform, which is designed to stimulate critical lymphocytes, in...